| Regular menstrual cycle | In one study, a regular cycle at month six was reported in 19 of 24 with the supplement and 15 of 24 with metformin alone.By month six, 19/24 versus 15/24; p<0.001 refers to the analysis of changes over time, not this direct comparison. | 1/4 Very lowEstimate precision: Small groups and no CI for the direct effect. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Adjunct comparison of a mixture; cannot be transferred to a single isomer. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Five of 53 were not included in the cycle-regularity denominators; blinding is unconfirmed. | 11 trialA randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome ↗ | 53 women aged 18–35 with PCOS and overweight or obesity; 26/27 randomized | - A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome ↗
|
|---|
| Ovulation assessed by progesterone | Over 6–8 weeks, ovulation was recorded in 19 of 22 women taking D-chiro-inositol and 6 of 22 on placebo.19/22 versus 6/22, p<0.001. | 2/4 LowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: The result was measured in the specified restricted group. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results. | 11 trialOvulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗ | 44 women with PCOS and obesity; 22 in each group | - Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗
|
|---|
| Systolic and diastolic blood pressure | In the D-chiro-inositol group of women with PCOS and obesity, both blood pressure measures fell by 4 mmHg from baseline over 6–8 weeks.Within-group change with D-chiro-inositol: systolic and diastolic pressure fell by 4 mmHg; this is not the size of the between-group difference. | 1/4 Very lowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: Restricted group, biomarker or combination product. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results. | 11 trialOvulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗ | 44 women with PCOS and obesity; 22 in each group | - Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗
|
|---|
| Plasma triglycerides | In the same study, triglycerides fell from 184 to 110 mg/dl in the D-chiro-inositol group over 6–8 weeks.D-chiro-inositol group: 184±88 → 110±61 mg/dl; no substantial change was observed in the placebo group. | 1/4 Very lowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: Restricted group, biomarker or combination product. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results. | 11 trialOvulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗ | 44 women with PCOS and obesity; 22 in each group | - Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗
|
|---|
| Sperm concentration | After three months, sperm concentration was 26.4 versus 20.8 million/ml in the myo-inositol plus folic acid and folic acid alone groups.20.2±4.6→26.4±4.4 versus 20.4±4.4→20.8±4.3 million/ml; p<0.05 for the final comparison. | 1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown. | 11 trialMyoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗ | 194 men younger than 45 with idiopathic infertility; 98/96 by group | - Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗
|
|---|
| Total sperm count | After three months, total sperm count was 57.6 versus 47.8 million per ejaculate.46.6±12.6→57.6±14.4 versus 47.2±12.2→47.8±11.2 million/ejaculate; p<0.05 for the final comparison. | 1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown. | 11 trialMyoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗ | 194 men younger than 45 with idiopathic infertility; 98/96 by group | - Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗
|
|---|
| Progressive motility | After three months, progressive motility was 27.6% versus 23.3%.22.2±2.1→27.6±1.8% versus 22.3±2.6→23.3±2.1%; p<0.05 for the final comparison. | 1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown. | 11 trialMyoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗ | 194 men younger than 45 with idiopathic infertility; 98/96 by group | - Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗
|
|---|
| Acrosome reaction | After three months, the acrosome reaction was 41% versus 36%.34±8→41±11% versus 35±8→36±10%; p<0.05 for the final comparison. | 1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown. | 11 trialMyoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗ | 194 men younger than 45 with idiopathic infertility; 98/96 by group | - Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study ↗
|
|---|
| Reported pregnancies | Over six months, three pregnancies were reported in each group; no added benefit of the inositol mixture was shown.3 pregnancies in each group; no confidence interval for the direct comparison is provided. | 1/4 Very lowrisk_of_bias: Five of 53 were not included in the cycle-regularity denominators; blinding is unconfirmed. inconsistency: No grounds for a separate downgrade. indirectness: Adjunct comparison of a mixture; cannot be transferred to a single isomer. imprecision: Small groups and no CI for the direct effect. publication_bias: No specific data supporting a separate downgrade. | 11 trialA randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome ↗ | 53 women aged 18–35 with PCOS and overweight or obesity, 26/27 randomized; denominators for the pregnancy analysis are not separately confirmed | - A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome ↗
|
|---|
| Oral glucose tolerance test | Over 6–8 weeks of D-chiro-inositol use in women with PCOS and obesity, no significant change in glucose tolerance was found on the oral test.No significant change in glucose tolerance was found on the oral test. | 1/4 Very lowrisk_of_bias: Small study, incomplete methods or selective outcomes inconsistency: Single comparison; consistency not assessable indirectness: Restricted population, biomarker or mixed preparation imprecision: Small trial or confidence interval covers important uncertainty publication_bias: No specific evidence, not excluded | 11 trialOvulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗ | 44 women with PCOS and obesity; 22 randomized to each group | - Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗
|
|---|